Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
3.930
-0.080 (-2.00%)
Oct 26, 2026, 2:32 PM EDT - Market open
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $50.53M in the quarter ending June 30, 2026, a decrease of -3.92%. This brings the company's total for the last twelve months to $215.72M, up 6.02% year-over-year. In the year 2025, Vanda Pharmaceuticals had annual revenue of $216.11M with 8.72% growth. That makes Vanda Pharmaceuticals the 16,905th largest company in the world by revenue and 2,833rd in the United States.
Revenue (ttm)
$215.72M
Revenue Growth
+6.02%
P/S Ratio
1.12
Revenue / Employee
$404,730
Employees
533
Market Cap
237.62M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 216.11M | 17.33M | 8.72% |
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | 227.19M | 34.07M | 17.64% |
| Dec 31, 2018 | 193.12M | 28.04M | 16.98% |
| Dec 31, 2017 | 165.08M | 19.07M | 13.06% |
| Dec 31, 2016 | 146.02M | 36.09M | 32.83% |
| Dec 31, 2015 | 109.93M | 59.77M | 119.16% |
| Dec 31, 2014 | 50.16M | 16.28M | 48.05% |
| Dec 31, 2013 | 33.88M | 1.15M | 3.52% |
| Dec 31, 2012 | 32.73M | 1.46M | 4.66% |
| Dec 31, 2011 | 31.27M | -4.44M | -12.43% |
| Dec 31, 2010 | 35.71M | 31.16M | 685.16% |
| Dec 31, 2009 | 4.55M | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Abeona Therapeutics | 25.52M |
| AC Immune | 21.67M |
| Fate Therapeutics | 6.49M |
| Ocugen | 4.58M |
VNDA News
- 4 days ago - Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 - PRNewsWire
- 11 days ago - Vanda says anxiety drug failed main goal of late-stage study, puts program on hold - Reuters
- 11 days ago - Vanda Pharmaceuticals: Phase 3 study of VQW-765 did not meet primary endpoint - TheFly
- 11 days ago - Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program - PRNewsWire
- 24 days ago - Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting - PRNewsWire
- 26 days ago - Vanda Pharmaceuticals reports results from pivotal Phase III study of HETLIOZ - TheFly
- 26 days ago - Vanda Pharmaceuticals up 33% after Phase 3 Hetlioz study met primary endpoint - TheFly
- 26 days ago - Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder - PRNewsWire